Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The spectrum of acute bacterial meningitis in elderly patients

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Pomar, Virginia|||0000-0002-8473-5834
  • Benito, Natividad|||0000-0001-6410-013X
  • Coll Figa, Pedro|||0000-0003-1782-9782
We conducted a prospective, observational study in Barcelona to determine the epidemiology, clinical features, and outcome of elderly patients with acute bacterial meningitis (ABM) compared with younger adults. During 1982-2010, all patients with ABM were prospectively evaluated. There were two groups: I (15-64 years) and II (≥ 65 years). All patients underwent clinical examination on admission and at discharge following a predefined protocol. We evaluated 635 episodes of ABM. The incidence was 4.03/100,000 (Group I) and 7.40 /100,000 inhabitants/year (Group II) (RR = 1.84; 95%CI: 1.56-2.17, P < 0.0001). Elderly patients had co-morbid conditions more frequently (P < 0.0001) and more frequently lacked fever (P = 0.0625), neck stiffness (P < 0.0001) and skin rash (P < 0.0001), but had an altered level of consciousness more often (P < 0.0001). The interval admission-start of antibiotic therapy was longer for elderly patients (P < 0.0001). Meningococcal meningitis was less frequent in elderly patients (P < 0.0001), whereas listerial (P = 0.0196), gram-negative bacillary (P = 0.0065), and meningitis of unknown origin (P = 0.0076) were more frequent. Elderly patients had a higher number of neurologic (P = 0.0009) and extra-neurologic complications (P < 0.0001). The overall mortality ratio was higher in elderly patients (P < 0.0001). Elderly people are at higher risk of having ABM than younger adults. ABM in the elderly presents with co-morbid conditions, is clinically subtler, has a longer interval admission-antibiotic therapy, and has non-meningococcal etiology. It is associated with an earlier and higher mortality rate than in younger patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Mallol, Roger
  • López Dupla, Miguel
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Blanco, Julià|||0000-0002-2225-0217
  • Cañellas, Nicolau
  • Rull, Anna|||0000-0002-8907-7754
  • Leal, Manuel
  • Correig, Xavier|||0000-0002-6902-3054
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Vidal, Francesc|||0000-0002-6692-6186
Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels

  • López-Dupla, Miguel
  • Maymó-Masip, Elsa
  • Martínez, Esteban|||0000-0002-6911-8846
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Leal, Manuel
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Arnedo, Mireia|||0000-0001-6248-7780
  • Ferrando-Martínez, Sara
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Alba, Verónica|||0000-0002-5925-9573
  • Gatell, José Mª|||0000-0002-4705-3244
  • Vendrell, Joan|||0000-0002-6994-6115
  • Vidal, Francesc|||0000-0002-6692-6186
  • Chacón, Matilde R.
Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. We sought to explore the relationship between HALS and circulating levels of soluble (s) TWEAK and its scavenger receptor sCD163. This was a cross-sectional multicenter study of 120 HIV-1-infected patients treated with a stable HAART regimen; 56 with overt HALS and 64 without HALS. Epidemiological and clinical variables were determined. Serum levels of sTWEAK and sCD163 levels were measured by ELISA. Results were analyzed with Student's t -test, Mann-Whitney U and χ 2 test. Pearson and Spearman correlation were used to estimate the strength of association between variables. Circulating sTWEAK was significantly decreased in HALS patients compared with non-HALS patients (2.81±0.2 vs. 2.94±0.28 pg/mL, p = 0.018). No changes were observed in sCD163 levels in the studied cohorts. On multivariate analysis, a lower log sTWEAK concentration was independently associated with the presence of HALS (OR 0.027, 95% CI 0.001-0.521, p = 0.027). HALS is associated with decreased sTWEAK levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Gallego-Escuredo, José Miguel
  • Torres, Ferran|||0000-0002-7355-7913
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Villarroya, Joan
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Rio, Luis del
  • Estrada, Vicente|||0000-0002-7795-5986
  • Girlat, Marta|||0000-0001-7968-4190
HIV-1/HAART-associated lipodystrophy syndrome (HALS) has been associated with exposure to stavudine (d4T) through mitochondrial dysfunction. We performed a 48-week study to assess the effects of switching from d4T to raltegravir (RAL) on metabolic and fat molecular parameters of patients with HALS. Forty-two patients with HALS and a median exposure to d4T.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Cabeza Brasa, María del Carmen
  • Torres, Ferran|||0000-0002-7355-7913
  • Salazar, Juliana|||0000-0002-3581-4499
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mateo, Maria Gracia
  • Martínez, Esteban|||0000-0002-6911-8846
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Fernandez, Irene
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Ribera, Esteban|||0000-0002-3752-8808
  • Vidal, Francesc|||0000-0002-6692-6186
  • Baiget Bastús, Montserrat
Low expression thymidylate synthase (TS) polymorphism has been associated with increased stavudine triphosphate intracellular (d4T-TP) levels and the lipodystrophy syndrome. The use of d4T has been associated with acute pancreatitis and peripheral neuropathy. However, no relationship has ever been proved between TS polymorphisms and pancreatitis and/or peripheral neuropathy. We performed a case-control study to assess the relationship of TS and methylene-tetrahydrofolate reductase (MTHFR) gene polymorphisms with acute pancreatitis and/or peripheral neuropathy in patients exposed to d4T. Student's t test, Pearson's correlations, one-way ANOVA with Bonferroni correction and stepwise logistic regression analyses were done. Forty-three cases and 129 controls were studied. Eight patients (18.6%) had acute pancreatitis, and 35 (81.4%) had peripheral neuropathy. Prior AIDS was more frequent in cases than in controls (OR = 2.36; 95%CI 1.10-5.07, P = 0.0247). L7ow expression TS and MTHFR genotype associated with increased activity were more frequent in patients with acute pancreatitis and/or peripheral neuropathy than in controls (72.1% vs. 46.5%, OR = 2.97; 95%CI: 1.33-6.90, P = 0.0062, and 79.1% vs. 56.6%, OR = 2.90, 95%CI: 1.23-7.41, P = 0.0142, respectively). Independent positive or negative predictors for the development of d4T-associated pancreatitis and/or peripheral neuropathy were: combined TS and MTHFR genotypes (reference: A+A; P = 0.002; OR = 0.34 [95%CI: 0.08 to 1.44], OR = 3.38 [95%CI: 1.33 to 8.57], OR = 1.13 [95%CI: 0.34 to 3.71]), nadir CD4 cell count.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Mateo, Maria Gracia
  • Pruvost, Alain
  • Torres, Ferran|||0000-0002-7355-7913
  • Salazar, Juliana|||0000-0002-3581-4499
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Fernandez, Irene
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Vidal, Francesc|||0000-0002-6692-6186
  • Baiget Bastús, Montserrat
  • Calle Martín, Óscar de la|||0000-0001-9717-053X
To assess in a cohort of Caucasian patients exposed to stavudine (d4T) the association of polymorphisms in pyrimidine pathway enzymes and HLA-B*40∶01 carriage with HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome (HALS). Three-hundred and thirty-six patients, 187 with HALS and 149 without HALS, and 72 uninfected subjects were recruited. The diagnosis of HALS was performed following the criteria of the Lipodystrophy Severity Grading Scale. Polymorphisms in the thymidylate synthase (TS) and methylene-tetrahydrofolate reductase (MTHFR) genes were determined by direct sequencing, HLA-B genotyping by PCR-SSOr Luminex Technology, and intracellular levels of stavudine triphosphate (d4T-TP) by a LC-MS/MS assay method. HALS was associated with the presence of a low expression TS genotype polymorphism (64.7% vs. 42.9%, OR = 2.43; 95%CI: 1.53-3.88, P<0.0001). MTHFR gene polymorphisms and HLA-B*40∶01 carriage were not associated with HALS or d4T-TP intracellular levels. Low and high expression TS polymorphisms had different d4T-TP intracellular levels (25.60 vs. 13.60 fmol/10 6 cells, P<0.0001). Independent factors associated with HALS were(OR [95%CI]: (a) Combined TS and MTHFR genotypes (p = 0.006, reference category (ref.): 'A+A'; OR for 'A+B' vs. ref.: 1.39 [0.69-2.80]; OR for 'B+A' vs. ref.: 2.16 [1.22-3.83]; OR for 'B+B' vs. ref.: 3.13, 95%CI: 1.54-6.35), (b) maximum viral load ≥5 log10 (OR: 2.55, 95%CI: 1.56-4.14, P = 0.001), (c) use of EFV (1.10 [1.00-1.21], P = 0.008, per year of use). HALS is associated with combined low-expression TS and MTHFR associated with high activity polymorphisms but not with HLA-B*40∶01 carriage in Caucasian patients with long-term exposure to stavudine.